B2M and glioblastoma: Adverse prognostic markers included AGR2, IL6, MMP9, and TIMP1, whereas PAK3, Notch1, and B2M were linked to more prolonged survival or therapeutic responsiveness, underscoring the molecular heterogeneity of GBM.